Mr. George Achilleos reports

NETRAMARK SIGNS CONTRACT WITH A LEADING GLOBAL BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS

Netramark Holdings Inc. has signed a new contract with a leading biopharmaceutical company to apply its NetraAI platform to a phase 3 clinical trial of a novel psychiatric medicine.

This represents continued industry penetration of the company's technology as a next-generation approach to understanding patient heterogeneity and optimizing study success rates.

Under the agreement, Netramark will deploy its proprietary AI (artificial intelligence) methodology to analyze multidimensional clinical data and identify explainable subpopulations -- associated with treatment response, placebo response and adverse events. The insights generated will support future strategic regulatory and market access activities.

"This project reflects the growing recognition among biopharmaceutical companies that Netramark's explainable AI can improve the chance of trial success," said George Achilleos, chief executive officer of Netramark. "NetraAI aims to provide clear, scientifically and clinically interpretable outputs that sponsors can act on -- helping them to understand precisely who benefits most, why and how to design their next pivotal studies with greater confidence."

Netramark's NetraAI platform leverages a dynamical systems framework that seeks to overcome the limitations of traditional machine learning, allowing it to work effectively even with small, complex clinical data sets. The system strives to discover high-effect-size patient subpopulations and translate them into clinically meaningful enrichment criteria that can be understood by investigators, regulators and clinicians alike.

This engagement further extends Netramark's growing portfolio of AI-driven projects in neuroscience, oncology and complex pain as the company continues to demonstrate its capacity to deliver actionable precision-trial insights that support drug development success for its clients.

About NetraAI

In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small data sets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses as well as adverse events), providing the potential to increase the chances of a clinical trial success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to overfitting, which drowns out critical information that could have been used to improve a trial's chance of success.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of generative artificial intelligence (gen AI)/machine learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.